All News
Filter News
Found 806,114 articles
-
McKesson Corporation Announces Pricing Terms of Tender Offer for Any and All 3.796% Notes Due 2024
6/13/2023
McKesson Corporation announced the pricing terms of its previously announced offer to purchase for cash any and all of its outstanding 3.796% Notes due 2024.
-
Accelerate Diagnostics Announces Successful Completion of Debt Restructuring Support Agreement, Supporting Advancement of Next-Generation Platform Wave
6/13/2023
Accelerate Diagnostics, Inc., a leading provider of innovative rapid diagnostic solutions, has closed the transactions contemplated by the previously announced restructuring support agreement.
-
American College of Gastroenterology and American Gastroenterological Association Invest in Oshi Health to Accelerate Adoption of Hybrid Digestive Health Care
6/13/2023
Oshi Health announced strategic investments by the American College of Gastroenterology and the American Gastroenterological Association GI Opportunity Fund.
-
FDA Roundup: June 13, 2023
6/13/2023
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.
-
Aviv Clinics Spotlights New Hyperbaric Oxygen Therapy Study Sharing Its Effect on Myocardial Function in Post-COVID-19 Patients
6/13/2023
Aviv Clinics, one of the most advanced medical clinics in the world, is sharing the results of a new study that shows that a unique hyperbaric oxygen therapy protocol is effective for post-COVID-19 patients suffering from cardiac dysfunction.
-
Genezen Announces the Appointment of Key Executive Leaders, Expanding Viral Vector Capabilities
6/13/2023
Genezen, a gene and cell therapy contract development and manufacturing organization, announced the appointment of Susan D'Costa, Ph.D. as Chief Technology Officer and Nicole O'Brien, Ph.D. as Chief Commercial Officer.
-
RadNet Announces Proposed $175 Million Underwritten Public Offering of Common Stock
6/13/2023
RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, announced that it intends to offer and sell, subject to market and other conditions, an underwritten public offering of $175,000,000 of shares of common stock.
-
Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular DystrophySafety and Efficacy Results to be Presented at 2023 Parent Project Muscular Dystrophy Annual Conference
6/13/2023
Capricor Therapeutics announced that the Company will present 24-month safety and efficacy results from its ongoing HOPE-2 open-label extension study with its lead asset, CAP-1002, for the treatment of Duchenne Muscular Dystrophy at this year’s Parent Project Muscular Dystrophy Annual Conference.
-
Scientific Industries Announces Retirement of Member of Board of Directors
6/13/2023
Scientific Industries, Inc., a life sciences tool provider, and a developer of digitally simplified bioprocessing products, announced that Joseph G. Cremonese, a member of the Company's board of directors is retiring and has therefore, resigned, from the Company's Board of Directors, effective June 13, 2023.
-
VA Oklahoma City Healthcare System Chooses ViewRay's MRIdian® MRI-Guided Radiation Therapy System
6/13/2023
ViewRay, Inc. announced that the VA Oklahoma City Healthcare System has selected MRIdian MRI-guided radiation therapy system to expand radiation therapy services at the Oklahoma City VA Medical Center.
-
Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
6/13/2023
Virpax® Pharmaceuticals, Inc. announced that Company CEO Anthony P. Mack has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET The exponential growth in knowledge and expertise in science and medicine continues to drive opportunities in the healthcare space.
-
Medexus Highlights Data on Trecondyv (Treosulfan) Presented at MDS 2023
6/13/2023
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 13, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to highlight positive new data on treosulfan that researchers at Toronto's Princess Margaret Hospital (PMH) recently presented at MDS 2023, the 17th annual International Congress on Myelodysplastic Syndromes, held in Marseille, France.
-
ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer
6/13/2023
ITM Isotope Technologies Munich SE announced the opening of its new production facility for therapeutic radionuclides in Neufahrn near Munich, Germany in the presence of Minister of State, Dr. Florian Herrmann and other high-ranking guests.
-
Advancements in Multiomics: Automation of Opal Staining on NanoVIP Saves 80% Reagent Cost and 90% Hands-on Time
6/13/2023
Omicsveu has achieved a milestone with its NanoVIP instrument – a slide-based automated staining system - fully automating the Opal manual staining protocol from Akoya Biosciences.
-
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market
6/13/2023
Aytu BioPharma, Inc. announced the closing of its equity offering co-led by Nantahala Capital Management and Stonepine Capital Management with participation by Armistice Capital of 1,743,695 shares of its common stock.
-
Masimo Board of Directors Highlights Value of Company’s Mission-Driven Innovation in Letter to Stockholders
6/13/2023
The Board of Directors of Masimo Corporation issued a letter to stockholders in connection with the Company’s Annual Meeting of Stockholders to be held on June 26, 2023.
-
Genomill and Finland's Cancer Research Flagship iCAN Partner To Improve Cancer Detection Using an Extensive Biobank Cohort
6/13/2023
Genomill and iCAN, the Finnish national cancer research flagship project, signed a partnership aiming to improve the detection of trace tumour DNA from thousands of biobank samples.
-
RETRANSMISSION: Braxia Scientific Reports a 26% Increase in Total Treatment Volumes in F2023 and an 87% Increase in Treatments at Newly Expanded Ottawa Clinic
6/13/2023
Toronto, Ontario--(Newsfile Corp. - June 12, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia", or the "Company"), a medical research company with mental health clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to report treatment volumes across its clinics increased 26.2% to 3,516 from 2,785 treatments on a year-over-year basis in Fiscal 2023.
-
eGenesis Announces Publication in Nature Communications Characterizing Renal Physiology and Endocrine Function in Non-Human Primates Post Xenograft Transplant
6/13/2023
eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, announced the publication of a paper in the journal Nature Communications highlighting novel findings from the largest cohort of long-term non-human primate recipients of porcine kidney xenotransplantation to date.
-
Danish National Genome Center selects QIAGEN for variant interpretation in oncology genome sequencing
6/13/2023
QIAGEN announced that its variant interpretation and reporting software, QIAGEN Clinical Insight Interpret, is being deployed as a part of a national initiative in Denmark to offer sequencing-based solutions for cancer patients.